Association of early immune-related adverse events with treatment efficacy of neoadjuvant Toripalimab in resectable advanced non-small cell lung cancer

• DOI: 10.3389/fonc.2023.1135140
• Publication Date: 2023-05-15T16:02:54Z
• Authors: Ye Tao; Xiang Li; Bing Liu; Jia Wang; Chao Lv; Shaolei Li; Yuzhao Wang; Jinfeng Chen; Shi Yan; Nan Wu
• Keywords: Neoadjuvant Therapy

Neoadjuvant immunotherapy with anti-PD-1 was proved promising in resectable non-small cell lung cancer (NSCLC). Immune-related adverse events (irAEs) have been preliminarily implicated their association treatment efficacy. Here we elucidated the early onset of irAEs associated better clinical outcomes a prospective study (Renaissance study).We conducted NSCLC patients treated by neoadjuvant Toripalimab (240mg, every 3 weeks) plus double platinum-based chemotherapy from December 2020 to March 2022 at Peking University Cancer Hospital. Patients were enrolled if they IIB-IIIB without EGFR/ALK mutation. Data analyzed explore relationship between outcome and after treatment. A multidisciplinary team including physicians, surgeons, radiologists, confirmed according manifestation. The pathological analyzed. Renaissance approved Ethic board (2020YJZ58) registered https://clinicaltrials.gov/ as NCT04606303.Fifty-five consecutive male-to-female ratio 10:1, median age 62 years old (IQR: 45-76), which 44 (80%) diagnosed squamous carcinoma. Forty-eight 55 finally received thoracic surgery preoperative waiting time 67 days (IQR 39-113 days). Pathological results demonstrated that 31 (64.6%) achieved major response (MPR) 24 (50.0%) complete (pCR). Among 48 who R0 resection, immunotherapy-related thyroid dysfunction, rash/pruritus enteritis occurred 11 (22.9%), 7 (14.6%), 1 patient (2.1%), respectively. Six (54.5%) dysfunction MPR 5 (45.5%) pCR, 45 21-91 (85.7%) rash or pruritus (71.4%) being 8 6-29 Furthermore, had no significant influence on operation (170.6 min vs 165.7 min, P=0.775), intraoperative blood loss (67.4 mL 64.3 mL, P=0.831) (93 97 days, P=0.630) when comparing (Figure 1).Figure 1Comparison (A), (B), (C) "with irAEs" "without irAEs".The is potentially chemo-immunotherapy, suggesting easy-to-find irAEs, such rash, can be used indicators predict chemo-immunotherapy.Clinical trial registration: clinicaltrials.gov/, identifier NCT04606303.